The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
What goes down must come up.
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
GE sells its Biopharma business for $21.4bn, but is its IPO cancelled or merely on hold?